Clinical Trial Update: Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of Dexmecamylamine (TC-5214) for overactive bladder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Dexmecamylamine (TC-5214) (dexmecamylamine)

Snippet

Sponsor: Targacept Inc. | Conditions: Overactive Bladder | Phase 2 | Status: COMPLETED